eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
5/2022
vol. 39
 
Share:
Share:
more
 
 
abstract:
Original paper

Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies

Hongyi Fu
1
,
Jing Guo
2

1.
Department of Medical Cosmetology Center, the first branch of The First Affilliated Hospital of Chongqing Medical University, Chongqing, China
2.
Department of Dermatology, Youyang People’s Hospital, Chongqing, China
Adv Dermatol Allergol 2022; XXXIX (5): 953-958
Online publish date: 2022/11/09
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
The efficacy of guselkumab versus adalimumab for psoriasis remains controversial.

Aim
We conducted a systematic review and meta-analysis to explore the influence of guselkumab versus adalimumab on treatment efficacy for psoriasis.

Material and methods
We have searched PubMed, Embase, Web of Science, EBSCO, and Cochrane library databases for randomized controlled trials (RCTs) published until March 2021 and assessing the efficacy and safety of guselkumab versus adalimumab for psoriasis. This meta-analysis was performed using the random-effects model.

Results
Three RCTs were included in the meta-analysis. Overall, compared with adalimumab for psoriasis, guselkumab was associated with improved PASI 100 (OR = 2.18; 95% CI: 1.47 to 3.23; p = 0.0001), PASI 90 (OR = 2.63; 95% CI: 2.11 to 3.27; p < 0.00001), PASI 75 (OR = 3.10; 95% CI: 2.35 to 4.08; p < 0.00001) and PGA 0/1 (OR = 2.04; 95% CI: 1.26 to 3.31; p = 0.004), as well as decreased DLQI (SMD = –0.24; 95% CI: –0.34 to –0.13; p < 0.00001). In addition, guselkumab resulted in higher DLQI score 0/1 (OR = 1.88; 95% CI: 1.51 to 2.33; p < 0.00001) than adalimumab.

Conclusions
Guselkumab showed better efficacy than adalimumab for psoriasis.

keywords:

guselkumab, adalimumab, psoriasis, efficacy, randomized controlled trials

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.